AMRX Amneal Pharmaceuticals Inc. Class A

Amneal to Report Third Quarter 2025 Results on October 30, 2025

Amneal to Report Third Quarter 2025 Results on October 30, 2025

BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at . Individuals may register for the webcast by clicking the link . To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this . The access code for the call is 272787. A replay of the conference call will be posted shortly after the call.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit  and follow us on .

Investor Contact

Anthony DiMeo

VP, Investor Relations



EN
30/09/2025

Underlying

AMRXAmneal Pharmaceuticals Inc. Class A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amneal Pharmaceuticals Inc. Class A

 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Reports Third Quarter 2025 Financial Results

Amneal Reports Third Quarter 2025 Financial Results ‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ‒ BRIDGEWATER, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2025. “Amneal delivered another strong quarter and updated our 2025 outlook, underscoring the strength of our diversified business and the ...

October 30, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropi...

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segment BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has tentatively approved the Company’s Abbreviated New Drug Application (ANDA) for beclomethasone dipropionate HFA inhalation aerosol (40 mcg/actuation and 80 mcg/actuation). The product is th...

October 29, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adu...

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the U.S. commercial launch of Brekiya® (dihydroergotamine mesylate) injection, the first and only ready-to-use dihydroergotamine (DHE) autoinjector...

October 27, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal to Report Third Quarter 2025 Results on October 30, 2025

Amneal to Report Third Quarter 2025 Results on October 30, 2025 BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at . Individuals may register for the webcast by ...

September 30, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (om...

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab) Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal BRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC. XOLAIR® is a registered trademark of Novartis AG. Omalizumab, a humani...

September 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch